SCHEMBL3900927

SCHEMBL3900927

CC1(C)CC=C(c2cc(C3(CN4CCOCC4)CCOCC3)ccc2C(N)=O)CC1

nearest known ligand 0.58

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.39
KIT P10721 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
F10 P00742 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16320166 0.95 SLC6A2 (0.36) CSF1RKITSLC6A2SLC6A4SLC6A3
SCHEMBL3901833 0.87
SCHEMBL3913620 0.87
SCHEMBL5474077 0.86 SLC6A2 (0.43) CSF1RKITSLC6A2SLC6A4SLC6A3
SCHEMBL3903584 0.85 SLC6A4 (0.37) SLC6A4SLC6A3
SCHEMBL3902025 0.85 SLC6A2 (0.43) CSF1RKITSLC6A2SLC6A4SLC6A3
SCHEMBL16320580 0.85 SLC6A4 (0.35) SLC6A4SLC6A3
SCHEMBL16319912 0.83 CSF1R (0.36) CSF1RKIT
SCHEMBL16319873 0.82
SCHEMBL3164430 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 EP disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
EP-2016070-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 EP disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885SLC6A2 3973/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885SLC6A2 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.